OPKO Health Narrows Q2 Loss to $8.4M as Pharma Segment Turns Profitable
OPK sits 44% above its 52-week low of $0.977.
Summary
OPKO Health reported a sharply narrower Q2 2026 net loss of $8.4 million, with the pharmaceutical segment turning profitable and the diagnostics segment boosted by a one-time earnout. The results mark a significant step toward financial stabilization.
Key Events · Earnings and Guidance · OPK
-
Net Loss Narrows to $8.4M
Q2 2026 net loss was $8.4 million, a 94% improvement from $148.4 million in Q2 2025, driven by higher IP revenue and lower interest expense.
-
Pharma Segment Turns Profitable
The pharmaceutical segment posted operating income of $0.8 million vs a $28.7 million loss last year, boosted by $29.4 million in revenue from Nicoya equity and higher NGENLA royalties.
-
Diagnostics Segment Swings to Profit
Diagnostics operating income was $4.8 million vs a $18.2 million loss, helped by an $18.4 million earnout from the Labcorp oncology sale and cost reductions.
-
Cash Position Remains Strong
Cash, equivalents, and restricted cash totaled $314.4 million at June 30, 2026, down from $369.1 million at year-end 2025, with $62.8 million used in operations during H1 2026.
Analysis · OPK · Life Sciences
A dramatic year-over-year improvement marks OPKO Health's Q2 2026 results, with the net loss shrinking to $8.4 million from $148.4 million. The pharmaceutical segment swung to an operating profit of $0.8 million, driven by a $29.4 million revenue boost from an equity stake in Nicoya and higher royalties. The diagnostics segment also turned profitable, aided by an $18.4 million earnout from the Labcorp sale. With $314.4 million in cash and a much-reduced cash burn, the company's near-term survival risk has diminished significantly, though the core business remains unprofitable on an operating basis.
At the time of this filing, OPK was trading at $1.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $936.3M. The 52-week trading range was $0.98 to $1.61. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.